McDermott Advises AbolerIS Pharma on its Series A Financing Round - McDermott Will & Emery

McDermott Advises AbolerIS Pharma on its Series A Financing Round


McDermott Will & Emery advised AbolerIS Pharma (AbolerIS), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, on its Series A financing.

The round was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital, with participation from SFPI-FPIM, WE (Wallonie Entreprendre), Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital.

This funding will enable AbolerIS to accelerate the development of its lead program in clinical trials and to explore its effectiveness in additional autoimmune diseases.

The McDermott team that advised AbolerIS comprised:

  • Anthony Paronneau, partner, and Lucie Martin, associate, on corporate aspects
  • Sabine Naugès, partner, and Benoit Feroldi, associate, on regulatory aspects
  • Côme de Saint-Vincent, counsel, on tax issues

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.